1. Home
  2. FLUX vs BCDA Comparison

FLUX vs BCDA Comparison

Compare FLUX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flux Power Holdings Inc.

FLUX

Flux Power Holdings Inc.

HOLD

Current Price

$0.74

Market Cap

14.3M

Sector

Miscellaneous

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.02

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLUX
BCDA
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
14.1M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
FLUX
BCDA
Price
$0.74
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
181.7K
229.9K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
N/A
N/A
Revenue
$9,317,000.00
$479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$23.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
126.25
N/A
52 Week Low
$0.47
$0.75
52 Week High
$7.55
$2.29

Technical Indicators

Market Signals
Indicator
FLUX
BCDA
Relative Strength Index (RSI) 58.64 55.95
Support Level $0.49 $0.79
Resistance Level $1.18 $0.99
Average True Range (ATR) 0.07 0.06
MACD 0.03 0.01
Stochastic Oscillator 73.37 96.06

Price Performance

Historical Comparison
FLUX
BCDA

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: